表紙
市場調查報告書

多發性硬化症 (MS) :機會評估,流行病學預測,市場動態,開發平台分析

Multiple Sclerosis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019

出版商 GervanoRA Data Services LLP 商品編碼 769582
出版日期 內容資訊 英文 212 Pages
訂單完成後即時交付
價格
Back to Top
多發性硬化症 (MS) :機會評估,流行病學預測,市場動態,開發平台分析 Multiple Sclerosis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019
出版日期: 2020年01月03日內容資訊: 英文 212 Pages
簡介

本報告提供全球多發性硬化症 (MS) 治療藥市場相關調查分析,以現在·未來的機會為焦點,提供市場價值,專利分析,市場佔有率等相關的系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 疾病概要

  • 疾病定義與症狀
  • 病因與分類
  • 疾病診斷
  • 治療流程和指南
  • 流行病學與疾病負擔
  • 流行病學預測

第4章 市場動態

  • 政府法規的趨勢與影響
  • 價格與償付
  • 交易 (M&A,聯盟)
  • 新藥的認證 (美國FDA)
  • 新藥的認證 (EMA)
  • 專利分析 (失效,學名藥)

第5章 開發平台分析

  • 開發平台分析:各開發階段
  • 開發平台分析:各地區
  • 開發平台分析:各給藥途徑
  • 開發平台分析:各藥物類別
  • 開發平台分析:各作用機制
  • 開發平台分析:各大學·機關

第6章 核准計劃的預測

第7章 多發性硬化症 (MS) 治療藥臨床實驗摘要

  • 多發性硬化症 (MS) 治療藥的開發平台分析:臨床實驗結果別
  • 進行中的臨床實驗摘要
  • 計劃中臨床實驗摘要
  • 最近完成的臨床實驗摘要

第8章 現在·未來的競爭情形

  • 企業
  • 大學·機關

第9章 簡稱

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GERPH504

GervanoRA's pipeline analysis and opportunity assessment report "Multiple Sclerosis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019 " analyzed and assessed Multiple Sclerosis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Multiple Sclerosis industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Multiple Sclerosis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Multiple Sclerosis industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Route of Administration, Pipeline Analytics by Drug Class, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Stage of development, and Pipeline Analytics by Companies.

Our comprehensive analysis on the Multiple Sclerosis drug pipeline identified a total of 90 drug candidates undergoing different stages of development- from Early R&D to Pre-registration stage. Among these, eleven molecules are in the Phase 3 stage of development, sixteen molecules are in Phase 2, seventeen molecules are in Phase 1 and a total of 44 molecules are in non clinical stage of development. A majority of the molecules, i.e., 25 molecules in the drug pipeline are undergoing preclinical activities. Two drug candidates are in their Pre-registration stage.

The report has covered more than 80 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 15 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast till 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analytics of Pipeline Molecules and Approved Drugs
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines of all Late Stage Pipeline Drug Candidates
  • Current and Future Competitive Landscape
  • Key Established Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2 EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN MULTIPLE SCLEROSIS COMPETITIVE SPACE
  • 2.3. KEY MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

3 DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. TREATMENT ALGORITHM AND GUIDELINES
  • 3.4. EPIDEMIOLOGY AND DISEASE BURDEN
  • 3.5. EPIDEMIOLOGY FORECAST
    • 3.5.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.5.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4 MARKET DYNAMICS

  • 4.1. DEALS (MERGERS/ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1 DEAL ANALYTICS BY DEAL TYPE
      • 4.1.1.1. MERGERS AND ACQUISITIONS
      • 4.1.1.2. COLLABORATION AGREEMENTS
      • 4.1.1.3. LICENSING AGREEMENTS
      • 4.1.1.4. FINANCING DEALS
      • 4.1.1.5. TERMINATION AGREEMENTS AND SETTLEMENTS
  • 4.2. NEW DRUG APPROVALS (US FDA) SINCE 2010
  • 4.3. NEW DRUG APPROVAL (EX-US) SINCE 2010
  • 4.4. PATENT ANALYTICS (EXPIRIES AND GENERICIZATION)
    • 4.4.1. PATENT ANALYTICS OF APPROVED PRODUCTS
    • 4.4.2. PATEN T ANALYTICS OF PIPELINE DRUGS

5 PIPELINE ANALYTICS

  • 5.1. PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. PRE-REGISTRATION MOLECULES
    • 5.1.2. PHASE 3 MOLECULES
    • 5.1.3. PHASE 2 MOLECULES
    • 5.1.4. PHASE 1 MOLECULES
    • 5.1.5. PRECLINICAL MOLECULES
    • 5.1.6. EARLY R&D MOLECULES
  • 5.2. PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYTICS BY DRUG CLASS
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYTICS BY MECHANISM OF ACTION
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYTICS BY COMPANY TYPE
  • 5.6. PIPELINE MOLECULES BY UNIVERSITY AND INSTITUTES - IN LICENSING AND OUT LICENSING OPPORTUNITIES

6 CLINICAL STAGE PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PHASE 3 PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES

MEDDAY PHARMA - MD1003

JOHNSON & JOHNSON - PONESIMOD

ADAMAS PHARMACEUTICALS - ADS-5102

GW PHARMACEUTICALS - SATIVEX

GENMAB - OFATUMUMAB

TG THERAPEUTICS - UBLITUXIMAB (TG-1101)

AB SCIENCE - MASITINIB

SANOFI - AUBAGIO (TERIFLUNOMIDE)

SANOFI - LEMTRADA (ALEMTUZUMAB)

MERCK KGAA - EVOBRUTINIB (M2951)

MAPI-PHARMA LTD - GLATIRAMER ACETATE (GA, COPAXONE) DEPOT

  • 6.2. PHASE 2 PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES

APITOPE - ATX-MS-1467

BIOGEN - OPICINUMAB

GENEURO/SERVIER - TEMELIMAB (GNBAC1)

REGENERX - RGN-352

BRAINSTORM CELL THERAPEUTICS - MSC-NTFS

MEDICINOVA - MN-166 (IBUDILAST)

ORYZON - ORY-2001

META-IQ - MIQ-001

FLEX PHARMA - FLX-787

MITSUBISHI TANABE PHARMA - MT-1303 (AMISELIMOD)

  • 6.3. PHASE 1 PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES

ATARA BIOTHERAPEUTICS - ATA188

ARRIEN PHARMA/BOSTON PHARMA - ARN-6039

GENERVON BIOPHARMACEUTICALS - GM6

DENALI THERAPEUTICS - DNL747

BIOGEN - BIIB061

BIOGEN - BIIB091

PRINCIPIA BIOPHARMA /SANOFI GENZYME - PRN2246

SANOFI - SAR441344

TIZIANA LIFE SCIENCES - TZLS-401 (FORALUMAB)

VACCINEX INC - VX15/2503

ACORDA - RHIGM22

IO THERAPEUTICS - IRX4204

NUTRA PHARMA - RPI-78M

7 ESTIMATED APPROVAL TIMELINES

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

8 OPPORTUNITY ASSESSMENT AND COMPETITIVE BENCH-MARKING

  • 8.1. EXTERNAL DEPENDENCIES
  • 8.2. PIPELINE PORTFOLIO
  • 8.3. EXPECTED MARKET ENTRIES
  • 8.4. PATENTS AND EXCLUSIVITY
  • 8.5. MARKET DYNAMICS AND PARTNERING
  • 8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 8.7. COMPANY DEVELOPMENTS

9 CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 9.1. ESTABLISHED COMPANIES
    • 9.1.1. KEY ESTABLISHED COMPANY PROFILES
      • 9.1.1.1. SANOFI
      • 9.1.1.2. ACORDA THERAPEUTICS INC
      • 9.1.1.3. BIOGEN
      • 9.1.1.4. NOVARTIS
  • 9.2. EMERGING COMPANIES
    • 9.2.1. EMERGING COMPANY PROFILES
      • 9.2.1.1. REVALESIO CORPORATION
      • 9.2.1.2. MEDDAY PHARMACEUTICALS
      • 9.2.1.3. ORYZON
      • 9.2.1.4. ATARA BIOTHERAPEUTICS
      • 9.2.1.5. PRINCIPIA BIOPHARMA
      • 9.2.1.6. GENEURO
      • 9.2.1.7. BIONURE
      • 9.2.1.8. ARRIEN PHARMACEUTICALS
      • 9.2.1.9. MAPI PHARMA
      • 9.2.1.10. TG THERAPEUTICS
      • 9.2.1.11. AB SCIENCE
      • 9.2.1.12. BRAINSTORM CELL THERAPEUTICS
      • 9.2.1.13. MEDICINOVA
      • 9.2.1.14. REGENERX
      • 9.2.1.15. DENALI THERAPEUTICS

10 ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02:TOTAL NO OF PEOPLE HAVING MS, PREVALENCE, MEAN ONSET OF AGE & FEMALE TO MALE RATIO
  • TABLE 03:TOTAL NO OF PEOPLE HAVING MS, PREVALENCE, MEAN ONSET OF AGE & FEMALE TO MALE RATIO IN EU
  • TABLE 04: GLOBAL MS EPIDEMIOLOGY (2016), FORECAST (2017-2023)
  • TABLE 05: MAJOR MERGERS AND ACQUISITIONS IN MS THERAPEUTIC AREA
  • TABLE 06: MAJOR COLLABORATIVE AGREEMENTS IN MS THERAPEUTIC AREA
  • TABLE 07: MAJOR LICENSING AGREEMENTS IN MS THERAPEUTIC AREA
  • TABLE 08: MAJOR FINANCING AGREEMENTS IN MS THERAPEUTIC AREA
  • TABLE 09: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN MS THERAPEUTIC AREA
  • TABLE 10: USFDA APPROVED DRUGS SINCE 2010
  • TABLE 11: EMA OR EX-US DRUG APPROVALS SINCE 2010
  • TABLE 12: GILENYA PATENTS
  • TABLE 13: TECFIDERA PATENTS
  • TABLE 14: PLEGRIDY PATENTS
  • TABLE 15: AMPYRA/FAMPYRA PATENTS
  • TABLE 16: AUBAGIO PATENTS COVERAGE AND EXPIRY
  • TABLE 17: LEMTRADA PATENTS COVERAGE AND EXPIRY
  • TABLE 18: ZYNBRYTA PATENTS
  • TABLE 19: PHASE 3 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 20: PHASE 2 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 21: PHASE 1 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 22: PRECLINICAL MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 23: EARLY R&D MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 24: ORALLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 25: INTRAVENOUSLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 26: SUBCUTANEOUSLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 27: MULTIPLE SCLEROSIS PIPELINE ANALYTICS BY COMPANY TYPE
  • TABLE 28: UNIVERSITY AND INSTITUTE'S PIPELINE MOLECULES FOR MS
  • TABLE 29: APPROVAL TIMELINES COMPARISON, GERVANORA ESTIMATIONS V/S ACTUAL APPROVAL
  • TABLE 30: ESTIMATED APPROVAL TIMELINE OF KEY PIPELINE DRUGS FOR MULTIPLE SCLEROSIS
  • TABLE 31: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 32: REVENUES GAINED THROUGH THE SALE OF MAJOR PRODUCTS IN MILLION $
  • TABLE 33: SANOFI'S OWNED PATENTS COVERING DUPIXENT
  • TABLE 34: SANOFI'S DEVELOPMENT PIPELINE UNDER NEURODEGENERATION
  • TABLE 35: SANOFI'S DEVELOPMENT PIPELINE UNDER INFLAMMATION AND IMMUNOLOGY
  • TABLE 36: SANOFI'S DEVELOPMENT PIPELINE UNDER ONCOLOGY
  • TABLE 37: SANOFI'S DEVELOPMENT PIPELINE UNDER RARE DISEASES
  • TABLE 38: SANOFI'S DEVELOPMENT PIPELINE UNDER RARE BLOOD DISORDERS
  • TABLE 39: SANOFI'S DEVELOPMENT PIPELINE UNDER VACCINES
  • TABLE 40: SANOFI'S RESEARCH AND DEVELOPMENT ACTIVITITES
  • TABLE 41: SANOFI'S RECENT DEVELOPMENTS
  • TABLE 42: SANOFI'S ANTICIPATED MILESTONES
  • TABLE 43: ACORDA'S MAJOR PRODUCTS
  • TABLE 44: AMPYRA PATENT EXPIRIES
  • TABLE 45: RESEARCH AND DEVELOPMENT ACTIVITIES OF ACORDA
  • TABLE 46: RECENT DEVELOPMENTS MADE BY ACORDA
  • TABLE 47: BIOGEN'S PRODUCTS UNDER MULTIPLE SCLEROSIS AND NEUROIMMUNOLOGY
  • TABLE 48: BIOGEN'S PRODUCTS UNDER BIOSIMILARS
  • TABLE 49: BIOGEN'S PRODUCTS UNDER ANTI-CD20
  • TABLE 50: BIOGEN'S PRODUCTS UNDER DEVELOPMENT
  • TABLE 51: BIOGEN'S PATENTS COVERING THEIR PRODUCTS UNDER MULTIPLE SCLEROSIS
  • TABLE 52: BIOGEN'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 53: BIOGEN'S RECENT DEVELOPMENTS
  • TABLE 54: BIOGEN'S ANTICIPATED MILESTONES
  • TABLE 55: NOVARTIS'S SALES IN MILLION $ OF TOP 10 PRODUCTS IN 9 MONTHS IN 2019
  • TABLE 56: NOVARTIS'S PATENTS COVERING GILENYA
  • TABLE 57: NOVARTIS'S IN REGISTRATION MOLECULES
  • TABLE 58: NOVARTIS'S PHASE 3 MOLECULES
  • TABLE 59: NOVARTIS'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 60: NOVARTIS'S RECENT DEVELOPMENTS
  • TABLE 61: NOVARTIS'S ANTICIPATED MILESTONES
  • TABLE 62: REVALESIO PRODUCT PIPELINE
  • TABLE 63: REVALESIO RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 64: REVALESIO RECENT DEVELOPMENTS
  • TABLE 65: MEDDAY PRODUCT PIPELINE
  • TABLE 66: MEDDAY RECENT DEVELOPMENTS
  • TABLE 67: MEDDAY EVENTS
  • TABLE 68: MEDDAY COLLABORATIONS
  • TABLE 69: ORYZON PRODUCT PIPELINE
  • TABLE 70: ORYZON RESEARCH AND DEVELOPMENTS
  • TABLE 71: ORYZON RECENT DEVELOPMENTS
  • TABLE 72: ORYZON EVENTS
  • TABLE 73: ATARA BIOTHERAPEUTICS PRODUCT PIPELINE
  • TABLE 74: ATARA BIOTHERAPEUTICS RESEARCH AND DEVELOPMENTS
  • TABLE 75: ATARA BIOTHERAPEUTICS RECENT DEVELOPMENTS
  • TABLE 76: ATARA BIOTHERAPEUTICS PRESENTATIONS
  • TABLE 77: PRINCIPIA PRODUCT PIPELINE
  • TABLE 78: PRINCIPIA RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 79: PRINCIPIA RECENT DEVELOPMENT ACTIVITIES
  • TABLE 80: PRINCIPIA PRESENTATIONS
  • TABLE 81: GENEURO PRODUCT PIPELINE
  • TABLE 82: GENEURO RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 83: GENEURO RECENT DEVELOPMENTS
  • TABLE 84: BIONURE LEAD PRODUCT CANDIDATE
  • TABLE 85: BIONURE RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 86: BIONURE RECENT DEVELOPMENT ACTIVITIES
  • TABLE 87: BIONURE EVENTS
  • TABLE 88: ARRIEN PHARMACEUTICALS PRODUCT PIPELINE
  • TABLE 89: ARRIEN PHARMACEUTICALS RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 90: ARRIEN PHARMACEUTICALS RECENT DEVELOPMENTS
  • TABLE 91: ARRIEN PHARMACEUTICALS PUBLICATIONS
  • TABLE 92: ARRIEN PHARMACEUTICALS CONFERENCES
  • TABLE 93: ARRIEN PHARMACEUTICALS PRESENTATIONS
  • TABLE 94: MAPI PRODUCT PIPELINE
  • TABLE 95: MAPI RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 96: MAPI RECENT DEVELOPMENT ACTIVITIES
  • TABLE 97: MAPI EVENTS AND PRESENTATIONS
  • TABLE 98: TG THERAPEUTICS PRODUCT PIPELINE
  • TABLE 99: TG THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 100: TG THERAPEUTICS PRESENTATIONS
  • TABLE 101: TG THERAPEUTICS CONFERENCES
  • TABLE 102: AB SCIENCE PRODUCT PIPELINE
  • TABLE 103: AB SCIENCE RECENT DEVELOPMENT ACTIVITIES
  • TABLE 104: AB SCIENCE RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 105: AB SCIENCE PRESENTATIONS
  • TABLE 106: BRAINSTORM CELL THERAPEUTICS PRODUCT PIPELINE
  • TABLE 107: BRAINSTORM CELL THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 108: BRAINSTORM CELL THERAPEUTICS RECENT DEVELOPMENTS
  • TABLE 109: BRAINSTORM CELL THERAPEUTICS PRESENTATIONS
  • TABLE 110: MEDICINOVA PRODUCT PIPELINE
  • TABLE 111: MEDICINOVA RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 112: MEDICINOVA RECENT DEVELOPMENT ACTIVITIES
  • TABLE 113: MEDICINOVA PRESENTATIONS
  • TABLE 114: MEDICINOVA COLLABORATIONS
  • TABLE 115: REGENERX PRODUCT PIPELINE
  • TABLE 116: REGENERX RESEARCH AND DEVELOPMENTS
  • TABLE 117: REGENERX RECENT DEVELOPMENTS
  • TABLE 118: REGENERX CONFERENCES
  • TABLE 119: DENALI PRODUCT PIPELINE
  • TABLE 120: DENALI PATENTS
  • TABLE 121: DENALI RESEARCH AND DEVELOPMENTS
  • TABLE 122: DENALI RECENT DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01: KEY EVENTS IN MULTIPLE SCLEROSIS DISEASE AREA
  • FIGURE 02: GLOBAL MS POPULATION FORECAST, IN MILLION
  • FIGURE 03: OVERALL DEALS ACTIVITY IN MS THERAPEUTIC AREA SINCE 2010
  • FIGURE 04: MULTIPLE SCLEROSIS PIPELINE DRUGS WITH RESPECT TO STAGES OF DEVELOPMENT
  • FIGURE 05: MULTIPLE SCLEROSIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 06: MULTIPLE SCLEROSIS PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 07: UNIVERSITY MOLECULES FOR MS, BY HSD
  • FIGURE 08: COMPARISON OF TOP COMPANIES BASED ON R&D INVESTMENTS IN MILLION $
  • FIGURE 09: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE 10: EXPECTED U.S MARKET ENTRY IRRESPECTIVE TO MULTIPLE SCLEROSIS MARKET
  • FIGURE 11: EXPECTED U.S MARKET ENTRY WITH RESPECT TO MULTIPLE SCLEROSIS MARKET
  • FIGURE 12: PATENT PORTFOLIO COMPARISON OF TOP 10 EMERGING COMPANIES
  • FIGURE 13: TIME LINE OF PATENT EXPIRIES IRRESPECTIVE TO MULTIPLE SCLEROSIS MARKET
  • FIGURE 14: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO MULTIPLE SCLEROSIS MARKET
  • FIGURE 15: RANKING TOP 10 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 16: RANKING TOP 10 EMERGING COMPANIES BASED ON THEIR REGULATORY ALLOWANCES
  • FIGURE 17: COMPARISON PIE CHARTS FOR INCOME GAINED THROUGH SALES IN 2018 AND 2019
  • FIGURE 18: FINANCIAL INFORMATION OF ACORDA FOR 2016, 2017 AND 2018
  • FIGURE 19: REVENUE BREAKDOWN BETWEEN ACORDA'S SEGMENTS FOR THE FIRST NINE MONTHS ENDED IN 2019
  • FIGURE 20: BIOGEN'S OPERATING EXPENSES IN MILLION $ FOR 2016, 2017 AND 2018
  • FIGURE 21: BIOGEN'S REVENUES ATTAINED FOR FIRST NINE MONTHS IN 2019
  • FIGURE 22: NOVARTIS'S REVENUES EARNED IN MILLION $ FOR 2016, 2017 AND 2018
  • FIGURE 23: NOVARTIS'S BREAKDOWN OF REVENUES EARNED IN THE YEAR END OF 2018
  • FIGURE 24: ATARA'S R&D EXPENSES FOR THREE MONTHS ENDED SEPTEMBER 30, 2018-2019
  • FIGURE 25: PRINCIPIA'S R&D EXPENSES FOR THE YEAR ENDED DECEMBER 31, 2017-18
  • FIGURE 26: TG THERAPEUTICS R&D EXPENSES FOR THE YEAR ENDED DECEMBER 31, 2017-18
  • FIGURE 27: AB SCIENCE R&D EXPENSE FOR YEAR ENDED DECEMBER 31, 2017-18
  • FIGURE 28: BRAINSTORM'S R&D EXPENSE FOR YEAR ENDED DECEMBER 31, 2017-18
  • FIGURE 29: MEDICINOVA'S OPERATING EXPENSES FOR YEAR ENDED DECEMBER 31, 2018, 2017, 2016
  • FIGURE 30: RESEARCH AND DEVELOPMENT EXPENSES, MEDICINOVA
  • FIGURE 31: DENALI THRAPEUTICS R&D EXPENSES THREE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018
Back to Top